UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of April 2026
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On April 30, 2026, ProQR Therapeutics
N.V. (“ProQR”) issued a press release entitled “ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of
Directors.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
ProQR hereby incorporates by reference the information
contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File
No. 333-263166 and File No. 333-285767).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
PROQR THERAPEUTICS N.V. |
| |
|
| Date: April 30, 2026 |
By: |
/s/ Dennis Hom |
| |
|
Dennis Hom |
| |
|
Chief Financial Officer |
INDEX TO EXHIBITS
| Number |
|
Description |
| |
|
|
| 99.1 |
|
Press Release of ProQR Therapeutics N.V. on April
30, 2026. |
Exhibit 99.1
ProQR
Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
LEIDEN,
Netherlands & CAMBRIDGE, Mass., April 30, 2026 – ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage
company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology
platform, today announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Boehringer
Ingelheim, to its Board of Directors.
“We
are pleased to nominate Lykke to our Board of Directors,” said James Shannon, MD, Chairperson of the Board of ProQR Therapeutics.
“Her extensive experience in global drug development and broad perspective across therapeutic areas will complement the expertise
of our Board. As we continue to advance our pipeline and strategy, her insights will be valuable in supporting ProQR’s next phase
of growth.”
Dr. Hinsch
Gylvin is a seasoned pharmaceutical executive with more than 20 years of global leadership experience spanning all phases of drug development.
She currently serves as Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, where she leads the global medical
and clinical development organization across a broad range of therapeutic areas, including oncology, cardiometabolic diseases, immunology,
CNS, and rare diseases.
Prior
to joining Boehringer Ingelheim, Dr. Hinsch Gylvin held senior leadership roles at Novartis and AstraZeneca, where she led global
medical and development strategies across multiple therapeutic areas. Earlier in her career, she held roles of increasing responsibility
at Roche, Novo Nordisk and Lundbeck, gaining extensive experience in clinical development, regulatory strategy and global medical affairs.
Dr. Hinsch
Gylvin holds an MD from the University of Copenhagen and an Executive MBA from SBS Swiss Business School.
The
nomination will be submitted for shareholder approval at the Company’s upcoming Annual General Meeting of Shareholders. If appointed, Dr. Hinsch Gylvin will serve as an independent non-executive director.
About
Axiomer™
ProQR
is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class
of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single
nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR
(Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to
change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting
an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that
it will have a new function that helps prevent or treat disease.
About
ProQR
ProQR
Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation
RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single
nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for
both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our
pipeline with patients and loved ones in mind.
Learn
more about ProQR at www.proqr.com.
Forward
Looking Statements
This
press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as “continue,” "anticipate," "believe," "could," "estimate,"
"expect," "goal," "intend," "look forward to", "may," "plan," "potential,"
"predict," "project," "should," "will," "would" and similar expressions. Such forward-looking
statements include, but are not limited to, statements regarding our business, technology, strategy, preclinical and clinical model data;
plans to submit the nomination of Dr. Hinsch Gylvin for shareholder approval; Dr. Hinsch Gylvin’s role and expected contribution
to ProQR; the continued development and advancement of our Axiomer™ platform; and the therapeutic potential of our Axiomer
RNA editing oligonucleotides and product candidates. Forward-looking statements are based on management's beliefs and assumptions and
on information available to management only as of the date of this press release. Our actual results could differ materially from those
expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and
other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report
filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and
clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or
halted shortage and pressure on supply and logistics on the global market, economic sanctions, U.S. government shutdown and international
tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our
contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain
their own operations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply
interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical
trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to
initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits
of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability to obtain, and costs to
obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and
development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties;
and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical events
and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment.
Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume
no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required
by law.
ProQR
Therapeutics N.V.
Investor
and media contact:
Sarah
Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
